AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience.
ABBV
· Healthcare · Drug Manufacturers - General
· Market cap $367.87B
ABBV is trading near fair value. No urgent action needed.
QuantHub Research: Investment Thesis
Scaling Phase
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billion in 2026 revenue and adjusted EPS of $13.96 to $14.16, though a $744 million IPR&D charge in Q1 2026 lowered guidance from prior targets. The stock at $208.05 trades at a P/S of 6.09 and trailing P/E of 88.2 on depressed GAAP earnings, placing it in the expensive zone on a 5-year P/S basis. However, adjusted earnings power is substantially higher than GAAP, and the company generates robust free cash flow of $17.8 billion annually. The analyst consensus target of $254 implies meaningful upside, but the current price already embeds strong growth expectations. The stock recently pulled back 15% from its 52-week high, creating a more reasonable entry point. AbbVie earns a C grade reflecting a good business at an expensive valuation with limited margin of safety.
AbbVie trades at a P/S of 6.09, which sits between the 75th percentile (5.58) and 90th percentile (6.14) of its 5-year range, placing it in the expensive zone. The premium reflects investor confidence in the Humira-to-Skyrizi/Rinvoq transition, with immunology revenue growing 14% in 2025 and management guiding to $67 billion in 2026 revenue. The trailing GAAP P/E of 88x is misleading due to large non-cash amortization charges from prior acquisitions; on an adjusted EPS basis of roughly $14, the forward P/E is approximately 15x, which is reasonable for a large-cap pharma. The recent 15% pullback from the $244.81 52-week high has brought the stock closer to fair value but has not created a clear bargain.
12–18 Month Outlook
Over the next 18 months, AbbVie is expected to deliver on its $67 billion 2026 revenue target, driven primarily by continued Skyrizi and Rinvoq scaling and neuroscience growth. Humira erosion should decelerate as the base shrinks further. Adjusted operating margins should approach 49% as the revenue mix shifts toward higher-margin newer products. Key catalysts include potential FDA approval of Rinvoq for vitiligo and oncology pipeline readouts. Risks include IRA Medicare pricing negotiations impacting Imbruvica, further IPR&D charges from pipeline investments, and competitive launches in immunology. The stock should trade in a range anchored around the $210-$240 level absent a major positive or negative catalyst.
Bull vs Bear
Bull Case
Skyrizi and Rinvoq combined revenue exceeded $17.7 billion in 2025, growing over 50% year-over-year in recent quarters, and are on track to fully offset Humira losses by 2026 with 10-plus approved indications between them.
Neuroscience revenue grew 19.6% in 2025, driven by Botox Therapeutic and Vraylar, with the segment approaching $10 billion in annual revenue and further growth expected from migraine and psychiatry indications.
Free cash flow remains robust at $17.8 billion in 2025, supporting a 3.2% dividend yield and continued share repurchases while funding pipeline investments without straining the balance sheet.
Management targets 49% adjusted operating margins and $67 billion in 2026 revenue, representing 9.5% top-line growth as the Humira headwind diminishes and newer products scale.
The oncology pipeline is being rebuilt through strategic acquisitions including ImmunoGen ($10.1 billion), Cerevel ($8.7 billion), and a $650 million RC148 licensing deal, positioning the company for diversified long-term growth.
Bear Case
Humira sales continue to erode rapidly, declining approximately 50% year-over-year from the 2022 peak of $21.2 billion, and the remaining revenue tail could shrink faster than expected as more biosimilars enter the market.
The GAAP EPS of $2.36 in 2025 reflects massive amortization charges from prior acquisitions, and the gap between GAAP and adjusted earnings ($14-plus) raises questions about the sustainability of adjustments and true economic earnings.
Regulatory risk from Medicare price negotiations under the IRA could directly impact Imbruvica pricing starting 2026, while 340B discount mandates upheld by the Fifth Circuit further pressure margins.
Competitive threats are emerging in core immunology markets, with Johnson and Johnson receiving FDA approval for ICOTYDE, an oral psoriasis treatment that could erode Skyrizi and Rinvoq market share over time.
The $744 million IPR&D charge in Q1 2026 signals continued high spending on unproven pipeline assets, and the company carries significant debt with a net debt to EBITDA ratio of 2.26x.
Leadership & Competitive Position
Robert A. Michael
Tenure2 yrs
Beats guidance75% of qtrs
Capital allocationGood
Robert A. Michael became CEO in July 2024 after 31 years in the pharmaceutical industry, having served as AbbVie's CFO, COO, and president. He succeeded Richard Gonzalez, who led the company since its 2013 spinoff from Abbott. Michael's deep institutional knowledge and finance background support disciplined capital allocation. Under his leadership, AbbVie has maintained its dividend, executed strategic acquisitions in oncology and neuroscience, and delivered on the Humira replacement strategy. The transition has been smooth with no disruption to operations or strategy.
Competitive Moat
stable
intangible assetsbrandswitching costs
AbbVie holds leading market share in immunology with Skyrizi and Rinvoq growing rapidly across psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Immunology revenue of $30.4 billion in 2025 represents the largest franchise in the industry. Botox maintains a dominant position in both therapeutic and aesthetic neurotoxin markets with a manufacturing moat. The moat trajectory has stabilized as Humira losses are being offset by next-generation products, though oral competitors from J&J and others pose a medium-term threat.
Competitors: Johnson & Johnson (JNJ), Roche (RHHBY), Merck & Co. (MRK), Eli Lilly (LLY), Amgen (AMGN)
Disruption: Medium. Biosimilar competition for Humira is largely priced in, but emerging oral therapies in immunology and new oncology entrants could challenge market share in key therapeutic areas over the next 3-5 years.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
88.16x
73.48x
56.34x
20.76x
96.82x
P/S
6.09x
5.58x
5.04x
4.26x
6.69x
P/FCF
20.91x
12.42x
11.8x
10.52x
22.97x
P/S 6.09x vs 5yr range 4.26-6.69x (P25=4.93x, median=5.04x, P75=5.58x, P90=6.14x). Current P/S exceeds P90 threshold.
First quarter results will clarify the impact of the $744 million IPR&D charge and provide visibility on 2026 revenue trajectory toward the $67 billion target.
high impact
2026-H1
FDA decision on Rinvoq for vitiligo
Potential first systemic dermatology treatment approval would expand the immunology franchise into a new therapeutic area and add incremental revenue.
medium impact
2026-H2
Oncology pipeline readouts (Epkinly, Teliso-V)
Phase 3 data from lymphoma and solid tumor programs could validate the oncology pipeline rebuild and improve investor confidence in long-term diversification.
medium impact
2026
IRA Medicare pricing negotiations for Imbruvica
Imbruvica is among drugs subject to Medicare price negotiations, which could materially reduce pricing and profitability for this $3.3 billion revenue product.
high impact
2026-2027
Skyrizi and Rinvoq label expansion filings
Additional indication approvals in hidradenitis suppurativa, vitiligo, and other autoimmune conditions could extend the growth runway for the immunology franchise.
medium impact
Risks
Humira biosimilar erosion
high
Humira sales have declined approximately 50% from the 2022 peak of $21.2 billion. While largely priced in, the erosion pace could accelerate further, and remaining revenue provides less cushion than expected.
Regulatory pricing pressures
high
IRA Medicare price negotiations directly threaten Imbruvica revenue starting 2026. The Fifth Circuit upheld 340B discount mandates, further pressuring margins. Additional drugs may face negotiations in coming years.
GAAP vs adjusted earnings gap
medium
The large disparity between GAAP EPS of $2.36 and adjusted EPS of approximately $14 reflects substantial non-cash amortization from prior acquisitions, but investors should monitor whether adjusted figures accurately represent economic reality.
Competitive threats in immunology
medium
Johnson and Johnson's ICOTYDE oral psoriasis treatment and other emerging oral therapies could erode market share for injectable products like Skyrizi and Rinvoq over the medium term.
Pipeline execution risk
medium
AbbVie has invested over $19 billion in acquisitions (ImmunoGen, Cerevel) and faces execution risk on integrating these assets and advancing oncology and neuroscience pipeline candidates through clinical trials.
Growth Engines
Immunology (Skyrizi/Rinvoq)scaling
Skyrizi and Rinvoq combined revenue exceeded $17.7 billion in 2025 with 50-plus percent growth. The global autoimmune disease market is estimated at over $100 billion and growing, with expansion into vitiligo, hidradenitis suppurativa, and additional inflammatory bowel disease indications providing further runway.
Neuroscience (Botox/Vraylar)scaling
Neuroscience revenue reached approximately $9.8 billion in 2025, growing 19.6%. The CNS therapeutics market exceeds $80 billion globally, with Vraylar expanding in bipolar depression and Botox growing in chronic migraine and overactive bladder.
Oncology pipelineearly
Hematologic oncology revenue of approximately $6.7 billion in 2025 with Imbruvica and Venclexta as anchors. AbbVie is rebuilding its oncology pipeline through ImmunoGen and Cerevel acquisitions and the RC148 licensing deal, targeting the $200 billion-plus global oncology market.
Increases margin pressure from mandated drug discounts across the hospital channel.
2026-01-15
AbbVie licenses RC148 for $650 million upfront to expand oncology portfolio
Adds PD-1/VEGF backbone ADC to oncology pipeline, complementing existing ImmunoGen and Cerevel acquisitions.
2026-03-05
Johnson and Johnson receives FDA approval for ICOTYDE oral psoriasis treatment
Introduces a new oral competitive threat to AbbVie's injectable immunology franchise products Skyrizi and Rinvoq.
Original research. Not scraped from Wall Street.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.